Syntheses and anti-cancer activities of derivatives of tetrandrine and fangchinoline

Abstract

A series of derivatives of tetrandrine and fangchinoline was designed and synthesized to find more active anti-cancer compounds. Their anti-cancer activities were tested against human hepatocellular carcinoma BEL-7402 and PLC/PRF/5 cells, human lung adenocarcinoma A549 cells as well as human leukaemia K562 cells, and the structure-activity relationship(SAR) was also studied. All the compounds except B1 exhibited superior inhibitory activities against PLC/PRF/5 cells with half maximal inhibitory concentration(IC₅₀) values of less than 15 μmol/L, and compounds A2, A4, B2 and B4 showed IC₅₀ values of less than 9 μmol/L. Compounds A2, A6, B2 and B4 showed potent anti-cancer activities against all the tested cells with IC₅₀ values of less than 10 μmol/L. The results show that terandrine and fangchinoline derivatives are potential suppressors to human cancer.

Keywords

Tetrandrine / Fangchinoline / Derivative / Cytotoxicity

References

[1] Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. CA: a Cancer Journal for Clinicians, 2011, 61(2): 69.

[2] Kanavos P. Annals of Oncology, 2006, 17(Suppl.8): viii15.

[3] Bosch F X, Ribes J, Borràs J. Seminars in Liver Disease, 1999, 19(3): 271.

[4] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal T, Ahn S Y, Alvarado M, Anderson H R, Anderson L M, Andrews K G, Atkinson C, Baddour L M, Barker-Collo S, Bartels D H, Bell M L, Benjamin E J, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh S S, Coffeng L E, Colan S D, Colquhoun S, Colson K E, Condon J, Connor M D, Cooper L T, Corriere M, Cortinovis M, de Vaccaro K C, Couser W, Cowie B C, Criqui M H, Cross M, Dabhadkar K C, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais D C, Dharmaratne S D, Dorsey E R, Driscoll T, Duber H, Ebel B, Erwin P J, Espindola P, Ezzati M, Feigin V, Flaxman A D, Forouzanfar M H, Fowkes F G, Franklin R, Fransen M, Freeman M K, Gabriel S E, Gakidou E, Gaspari F, Gillum R F, Gonzalez-Medina D, Halasa Y A, Haring D, Harrison J E, Havmoeller R, Hay R J, Hoen B, Hotez P J, Hoy D, Jacobsen K H, James S L, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo J P, Knowlton L M, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz S E, Ohno S L, Mabweijano J, MacIntyre M F, Mallinger L, March L, Marks G B, Marks R, Matsumori A, Matzopoulos R, Mayosi B M, McAnulty J H, McDermott M M, McGrath J, Mensah G A, Merriman T R, Michaud C, Miller M, Miller T R, Mock C, Mocumbi A O, Mokdad A A, Moran A, Mulholland K, Nair M N, Naldi L, Narayan K M, Nasseri K, Norman P, O’Donnell M, Omer S B, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian J D, Rivero A P, Padilla R P, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope C A 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm J T, Rein D B, Remuzzi G, Rivara F P, Roberts T, De León F R, Rosenfeld L C, Rushton L, Sacco R L, Salomon J A, Sampson U, Sanman E, Schwebel D C, Segui-Gomez M, Shepard D S, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor J A, Thomas B, Tleyjeh I M, Towbin J A, Truelsen T, Undurraga E A, Venketasubramanian N, Vijayakumar L, Vos T, Wagner G R, Wang M, Wang W, Watt K, Weinstock M A, Weintraub R, Wilkinson J D, Woolf A D, Wulf S, Yeh P H, Yip P, Zabetian A, Zheng Z J, Lopez A D, Murray C J, AlMazroa M A, Memish Z A. Lancet, 2012, 380(9859): 2095.

[5] Ho L J, Chang D M, Chang M L, Kuo S Y, Lai J H. Journal of Rheumatology, 1999, 26(1): 14.

[6] Kwan C Y, Achike F I. Acta Pharmacologica Sinica, 2002, 23(12): 1057.

[7] Wang G, Lemos J R, Iadecola C. Trends in Pharmacological Sciences, 2004, 25(3): 120.

[8] Fournet A, Barrios A A, Munoz V, Hocquemiller R, Cave A. Phytotherapy Research, 1993, 7(4): 281.

[9] De Arias A R, Inchausti A, Ascurrat M, Fleitas N, Rodriguez E, Fournet A. Phytotherapy Research, 1994, 8(3): 141.

[10] Angerhofer C K, Guinaudeau H, Wongpanich V, Pezzuto J M, Cordell G A. Journal of Natural Products, 1999, 62(1): 59.

[11] Wright C W, Marshall S J, Russell P F, Anderson M M, Phillipson J D, Kirby G C, Warhurst D C, Schiff P L. Journal of Natural Products, 2000, 63(12): 1638.

[12] Zuo G Y, Li Y, Wang T, Han J, Wang G C, Zhang Y L, Pan W D. Molecules, 2011, 16(12): 9819.

[13] Wong C W, Seow W K, Zeng T S, Halliday W J, Thong Y H. International Journal of Immunopharmacology, 1991, 13(5): 579.

[14] Qin S N, Lü W W, Wang Q, Zhao Q C, Xu Y N. Chem. J. Chinese Universities, 2013, 34(12): 2745.

[15] Wan Z, Lu Y, Liao Q, Wu Y, Chen X. Plos One, 2012, 7(6): e39225.

[16] Xing Z, Zhang Y, Zhang X, Yang X, Ma Y, Pang D. Phytotherapy Research, 2013, 27(12): 1790.

[17] Wang F P, Wang L, Yang J S, Nomura M, Miyamoto K. Biological & Pharmaceutical Bulletin, 2005, 28(10): 1979.

[18] Wang F P, Wang L, Yang J S, Chen D, Jian X X. Preparation and Drug Composition of Bis-benzyl-isoquinoline Class Alkaloids, U.S. 6617335 B1, 2003.

[19] Wan Y C, Liu Y, Liu M, Song R, Wang X B. Medicine and Materia Medical Research, 2010, 22(1): 212.

[20] Wang N, Pan W D, Zhu M F, Zhang M, Hao X J, Liang G Y, Feng Y. British Journal of Pharmacology, 2011, 164(2b): 731.

[21] Zha Y, Yao Z J. Chinese Journal of Organic Chemistry, 2006, 26(1): 27.

[22] Zheng X, Wang X P, Liu Y M, Guo Y, Luo X, Yin S, Dai Q, Zhu Q N, Liao D F. Lishizhen Medicine and Materia Medical Research, 2011, 22(6): 1343.

[23] Xiang H L, Zheng X, Cao J G. Acta Pharmacologica Sinica, 2008, 24(10): 1370.